File Download
Supplementary
-
Citations:
- Appears in Collections:
Article: Remdesivir for the Treatment of Severe SARS-CoV-2 (COVID-19): A Systematic Review and Meta-Analysis
Title | Remdesivir for the Treatment of Severe SARS-CoV-2 (COVID-19): A Systematic Review and Meta-Analysis |
---|---|
Authors | |
Keywords | Remdesivir COVID-19 SARS-CoV-2 Systematic review Meta-analysis |
Issue Date | 2020 |
Publisher | Science Repository OÜ. |
Citation | International Journal of Regenerative Medicine, 2020, p. 1-8 How to Cite? |
Abstract | Background: Coronavirus Disease in 2019 (COVID-19) is a pandemic caused by SARS-CoV-2 infection. Over 53 million people have been infected with over 1.3 million deaths. However, there is no standard treatment or vaccines to date. Recently, several randomized controlled trials and cohort studies have demonstrated the efficacy of remdesivir for the treatment of severe COVID-19 patients. This is a systematic review and meta-analysis to define its efficacy.
Methods: A systematic review was done on databases (PubMed, Embase, Medline, Cochrane) on 9 Nov 2020. Search keywords were remdesivir, COVID-19, SARS-CoV-2, randomized controlled trials and cohort studies. Studies with high-evidence values were selected to evaluate its clinical efficacy in terms of risk ratio, time to clinical improvement, and mortality risk. Subgroup analysis was performed based on baseline hospitalization status, age and ethnicity.
Results: Of the 1328 studies, 6 studies were selected and pooled for meta-analysis. Remdesivir was associated with clinical improvement (risk ratio 1.14, 95% CI 1.02-1.28, p=0.02). It shortened the mean time of clinical improvement by 3.32 days (95% CI -4.37 to -2.28, p<0.001). However, its use was not associated with reduced mortality risk (risk ratio 0.75, 95% CI 0.40–1.40). In subgroup analysis, remdesivir was associated with clinical improvement in patients without the need of invasive ventilation (risk ratio 1.90, 95% CI 1.58-2.29, p<0.001; hazard ratio 2.22, 95% CI, 1.64-3.02), and age less than 70 years (risk ratio 2.14, 95% CI 1.39-3.28, p<0.001).
Conclusion: Remdesivir is effective in the treatment of severe COVID-19 patients, in particular those without invasive ventilation. |
Description | Open Access Journal |
Persistent Identifier | http://hdl.handle.net/10722/300530 |
ISSN |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yan, Z | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Lau, EHY | - |
dc.contributor.author | Lai, CL | - |
dc.date.accessioned | 2021-06-18T14:53:16Z | - |
dc.date.available | 2021-06-18T14:53:16Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | International Journal of Regenerative Medicine, 2020, p. 1-8 | - |
dc.identifier.issn | 2613-5914 | - |
dc.identifier.uri | http://hdl.handle.net/10722/300530 | - |
dc.description | Open Access Journal | - |
dc.description.abstract | Background: Coronavirus Disease in 2019 (COVID-19) is a pandemic caused by SARS-CoV-2 infection. Over 53 million people have been infected with over 1.3 million deaths. However, there is no standard treatment or vaccines to date. Recently, several randomized controlled trials and cohort studies have demonstrated the efficacy of remdesivir for the treatment of severe COVID-19 patients. This is a systematic review and meta-analysis to define its efficacy. Methods: A systematic review was done on databases (PubMed, Embase, Medline, Cochrane) on 9 Nov 2020. Search keywords were remdesivir, COVID-19, SARS-CoV-2, randomized controlled trials and cohort studies. Studies with high-evidence values were selected to evaluate its clinical efficacy in terms of risk ratio, time to clinical improvement, and mortality risk. Subgroup analysis was performed based on baseline hospitalization status, age and ethnicity. Results: Of the 1328 studies, 6 studies were selected and pooled for meta-analysis. Remdesivir was associated with clinical improvement (risk ratio 1.14, 95% CI 1.02-1.28, p=0.02). It shortened the mean time of clinical improvement by 3.32 days (95% CI -4.37 to -2.28, p<0.001). However, its use was not associated with reduced mortality risk (risk ratio 0.75, 95% CI 0.40–1.40). In subgroup analysis, remdesivir was associated with clinical improvement in patients without the need of invasive ventilation (risk ratio 1.90, 95% CI 1.58-2.29, p<0.001; hazard ratio 2.22, 95% CI, 1.64-3.02), and age less than 70 years (risk ratio 2.14, 95% CI 1.39-3.28, p<0.001). Conclusion: Remdesivir is effective in the treatment of severe COVID-19 patients, in particular those without invasive ventilation. | - |
dc.language | eng | - |
dc.publisher | Science Repository OÜ. | - |
dc.relation.ispartof | International Journal of Regenerative Medicine | - |
dc.rights | Creative Commons: Attribution 3.0 Hong Kong License | - |
dc.subject | Remdesivir | - |
dc.subject | COVID-19 | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | Systematic review | - |
dc.subject | Meta-analysis | - |
dc.title | Remdesivir for the Treatment of Severe SARS-CoV-2 (COVID-19): A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Lau, EHY: ehylau@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Lau, EHY=rp01349 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.doi | 10.31487/j.RGM.2020.04.01 | - |
dc.identifier.hkuros | 322878 | - |
dc.identifier.spage | 1 | - |
dc.identifier.epage | 8 | - |
dc.publisher.place | Estonia | - |